Trial Profile

A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALRN 6924 (Primary) ; Palbociclib (Primary)
Indications Colorectal cancer; Haematological malignancies; Liposarcoma; Merkel cell carcinoma; Peripheral T-cell lymphoma; Sarcoma; Solid tumours
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Acronyms All-comers
Sponsors Aileron Therapeutics; Rein Therapeutics

Most Recent Events

10 Jan 2025 According to Rein Therapeutics media release, Aileron Therapeutics announces rebranding to Rein Therapeutics
22 Jul 2021 Results published in the Clinical Cancer Research
13 Jul 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com